Neovascular Age-Related Macular Degeneration Management
Treatment Overview
- The American Academy of Ophthalmology recommends anti-VEGF therapy as the first-line treatment for neovascular (wet) age-related macular degeneration, with agents such as aflibercept, ranibizumab, brolucizumab, or bevacizumab administered via intravitreal injection 1
- The treatment algorithm for neovascular AMD involves medication options, including aflibercept, ranibizumab, brolucizumab, and bevacizumab, with specific dosing regimens and treatment protocols 1
Treatment Protocols
- The "treat-and-extend" regimen is frequently used in clinical practice and has shown similar efficacy to monthly dosing with fewer injections, according to the American Academy of Ophthalmology 1
- PRN regimens may be slightly less effective in maintaining initial visual gains with longer follow-up, as reported by the American Academy of Ophthalmology 1
Management of Complications
- Small subretinal hemorrhages can be managed with anti-VEGF therapy, while larger submacular hemorrhages may require pneumatic displacement procedures, tPA, or vitrectomy, although evidence is limited, as stated by the American Academy of Ophthalmology 1
- If there is an inadequate response to one anti-VEGF agent, consider switching to another, as approximately 50% of patients maintained visual acuity of 20/40 at 5-year follow-up in the CATT trial, according to the American Academy of Ophthalmology 1
Safety and Efficacy
- The American Academy of Ophthalmology reports that anti-VEGF therapy is associated with risks such as endophthalmitis (≤1.0% over 1 year), retinal tear or detachment, intraocular inflammation, and a theoretical risk of systemic thromboembolic events, although clinical trials have shown inconsistent results 1
- Topical povidone-iodine is recommended before injection, and routine antibiotic eye drops are not recommended, as stated by the American Academy of Ophthalmology 1
Long-Term Management
- Neovascular AMD typically requires ongoing treatment, and interruption of treatment may result in disease recurrence and vision loss, as shown in the CATT study, which found that vision gains during the first 2 years were not maintained at 5-year follow-up, but 50% of patients maintained visual acuity of 20/40, according to the American Academy of Ophthalmology 1
- The American Academy of Ophthalmology guidelines support maintenance treatment with anti-VEGF agents, such as Vabysmo 6mg, at approximately 8-week intervals for neovascular AMD, which is consistent with the current regimen for a patient with exudative age-related macular degeneration 1
- Extending the treatment interval to 10 weeks may result in disease recurrence, such as hemorrhage, supporting the clinical necessity of the 8-week interval 1
- Patients with neovascular AMD require continued treatment to prevent disease progression, with the goal of improving or maintaining best corrected visual acuity or visual field, or reducing the rate of vision decline or risk of more severe vision loss, as supported by clinical guidelines from the American Academy of Ophthalmology 1